Y J Bryson

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353
    Y J Bryson
    David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1752, USA
    HIV Clin Trials 9:115-25. 2008
  2. ncbi Pediatric HIV-1-specific cytotoxic T-lymphocyte responses suggesting ongoing viral replication despite combination antiretroviral therapy
    Natascha Ching
    Department of Pediatrics, Division of Pediatric Infectious Diseases, David Gefen School of Medicine at UCLA and Mattel Children s Hospital at UCLA, Los Angeles, California 90095, USA
    Pediatr Res 61:692-7. 2007
  3. ncbi Autologous neutralizing antibody to human immunodeficiency virus-1 and replication-competent virus recovered from CD4+ T-cell reservoirs in pediatric HIV-1-infected patients on HAART
    Natascha Ching
    Division of Pediatric Infectious Diseases, Department of Pediatrics, David Geffen School of Medicine at UCLA, Mattel Children s Hospital UCLA, Los Angeles, California 90095, USA
    AIDS Res Hum Retroviruses 26:585-91. 2010
  4. ncbi Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART)
    Natascha Ching
    Pediatric Infectious Diseases, Department of Pediatrics, David Geffen School of Medicine at UCLA, Mattel Children s Hospital at UCLA, 10833 Le Conte Avenue, 22 442 MDCC, Los Angeles, CA 90095, USA
    Eur J Pediatr 166:51-6. 2007
  5. ncbi Interferon-gamma decreases replication of primary R5 HIV-1 isolates in thymocytes
    Livia Pedroza-Martins
    Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, California 90095-1747, USA
    AIDS 20:939-42. 2006
  6. ncbi Decreased CD8 cell-mediated viral suppression and other immunologic characteristics of women who transmit human immunodeficiency virus to their infants
    S Plaeger
    Department of Pediatrics, UCLA School of Medicine, Los Angeles, CA 90095 1752, USA
    J Infect Dis 179:1388-94. 1999
  7. ncbi Effect of protease inhibitors combined with standard antiretroviral therapy on linear growth and weight gain in human immunodeficiency virus type 1-infected children
    D Dreimane
    Department of Pediatrics, Mattel Children s Hospital at UCLA, Los Angeles, CA, USA
    Pediatr Infect Dis J 20:315-6. 2001
  8. ncbi Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum
    R E Dickover
    Department of Pediatrics, UCLA School of Medicine, Los Angeles, California 90095, USA
    J Virol 75:2194-203. 2001
  9. ncbi Pharmacokinetics of oral zidovudine administered during labour: a preliminary study
    M Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA 02118, and Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN, USA
    HIV Med 8:451-6. 2007
  10. ncbi Correlation of immune activation during late pregnancy and early postpartum with increases in plasma HIV RNA, CD4/CD8 T cells, and serum activation markers
    Hong Ha M Truong
    University of California, San Francisco, California, USA
    Clin Vaccine Immunol 17:2024-8. 2010

Research Grants

  1. LOS ANGELES PEDIATRIC AIDS CLINICAL TRIALS UNIT
    Yvonne Bryson; Fiscal Year: 2006
  2. UCLA Los Angeles Brazil AIDS Consortium
    Yvonne Bryson; Fiscal Year: 2007
  3. BRAZILIAN AIDS PREVENTION TRIALS INTERNATIONAL NETWORK
    Yvonne Bryson; Fiscal Year: 2006

Collaborators

Detail Information

Publications12

  1. ncbi Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353
    Y J Bryson
    David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1752, USA
    HIV Clin Trials 9:115-25. 2008
    ..We studied the safety, antiviral effect, and pharmacokinetics of NFV and its M8 metabolite with two dosing regimens in combination with zidovudine (ZDV) and lamivudine (3TC) in HIV-infected pregnant women...
  2. ncbi Pediatric HIV-1-specific cytotoxic T-lymphocyte responses suggesting ongoing viral replication despite combination antiretroviral therapy
    Natascha Ching
    Department of Pediatrics, Division of Pediatric Infectious Diseases, David Gefen School of Medicine at UCLA and Mattel Children s Hospital at UCLA, Los Angeles, California 90095, USA
    Pediatr Res 61:692-7. 2007
    ..The long-term clinical implications of these findings remain to be determined...
  3. ncbi Autologous neutralizing antibody to human immunodeficiency virus-1 and replication-competent virus recovered from CD4+ T-cell reservoirs in pediatric HIV-1-infected patients on HAART
    Natascha Ching
    Division of Pediatric Infectious Diseases, Department of Pediatrics, David Geffen School of Medicine at UCLA, Mattel Children s Hospital UCLA, Los Angeles, California 90095, USA
    AIDS Res Hum Retroviruses 26:585-91. 2010
    ..The observation of baseline ANAB activity with earlier plasma against a later RCV suggests that the "latent" reservoir may be established early in life before HAART...
  4. ncbi Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART)
    Natascha Ching
    Pediatric Infectious Diseases, Department of Pediatrics, David Geffen School of Medicine at UCLA, Mattel Children s Hospital at UCLA, 10833 Le Conte Avenue, 22 442 MDCC, Los Angeles, CA 90095, USA
    Eur J Pediatr 166:51-6. 2007
    ..We therefore determined cellular and humoral immune responses to tetanus toxoid (TT) booster in perinatally HIV-1-infected children and adolescents receiving HAART...
  5. ncbi Interferon-gamma decreases replication of primary R5 HIV-1 isolates in thymocytes
    Livia Pedroza-Martins
    Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, California 90095-1747, USA
    AIDS 20:939-42. 2006
    ..Thus infection and depletion of functionally mature thymocytes that can produce endogenous IFN-gamma may mutually contribute to HIV-1 replication in the thymus and to reduced T-cell output...
  6. ncbi Decreased CD8 cell-mediated viral suppression and other immunologic characteristics of women who transmit human immunodeficiency virus to their infants
    S Plaeger
    Department of Pediatrics, UCLA School of Medicine, Los Angeles, CA 90095 1752, USA
    J Infect Dis 179:1388-94. 1999
    ..4 times greater risk of transmitting HIV to their infants. CD8 suppression and viral load were interrelated, but when either CD4 percent or AZT use was controlled for, suppression was still significant...
  7. ncbi Effect of protease inhibitors combined with standard antiretroviral therapy on linear growth and weight gain in human immunodeficiency virus type 1-infected children
    D Dreimane
    Department of Pediatrics, Mattel Children s Hospital at UCLA, Los Angeles, CA, USA
    Pediatr Infect Dis J 20:315-6. 2001
    ..Accelerated height velocity was sustained for at least 18 to 20 months...
  8. ncbi Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum
    R E Dickover
    Department of Pediatrics, UCLA School of Medicine, Los Angeles, California 90095, USA
    J Virol 75:2194-203. 2001
    ..These data indicate that different selective pressures, depending on the timing of transmission, may be involved in determining the pattern of maternal HIV-1 variant transmission...
  9. ncbi Pharmacokinetics of oral zidovudine administered during labour: a preliminary study
    M Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA 02118, and Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN, USA
    HIV Med 8:451-6. 2007
    ....
  10. ncbi Correlation of immune activation during late pregnancy and early postpartum with increases in plasma HIV RNA, CD4/CD8 T cells, and serum activation markers
    Hong Ha M Truong
    University of California, San Francisco, California, USA
    Clin Vaccine Immunol 17:2024-8. 2010
    ..The observed rise in plasma HIV RNA postpartum, which correlated with markers of immune activation, may have implications for enhanced transmission to infants through early breast-feeding and to sexual partners...
  11. ncbi A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains
    Samantha H Johnston
    Division of Pediatric Infectious Diseases, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    J Virol 83:11016-26. 2009
    ..Our affinity-profiling system may help to refine studies of R5 virus tropism and pathogenesis...
  12. ncbi Impact of cytokines on replication in the thymus of primary human immunodeficiency virus type 1 isolates from infants
    Livia Pedroza-Martins
    Department of Microbiology, Immunology, and Molecular Genetics, UCLA AIDS Institute, USA
    J Virol 76:6929-43. 2002
    ..Our studies suggest that coreceptor use by HIV primary isolates is important but is not the sole determinant of HIV pathogenesis in the thymus...

Research Grants4

  1. LOS ANGELES PEDIATRIC AIDS CLINICAL TRIALS UNIT
    Yvonne Bryson; Fiscal Year: 2006
    ..The core and developmental laboratories in both virology and immunology have the capability to provide new innovative assays to enhance the overall scientific agenda and support the clinical trials. ..
  2. UCLA Los Angeles Brazil AIDS Consortium
    Yvonne Bryson; Fiscal Year: 2007
    ..The LABAC CTU and CRS are successful units with the infrastructure and experience needed for the conduct of both complex and multicenter NIH Network trials. ADMINISTRATIVE COMPONENT: ..
  3. BRAZILIAN AIDS PREVENTION TRIALS INTERNATIONAL NETWORK
    Yvonne Bryson; Fiscal Year: 2006
    ..abstract_text> ..